Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKinsey
QuintilesIMS
McKesson
Cantor Fitzgerald
Merck

Generated: April 19, 2019

DrugPatentWatch Database Preview

Anidulafungin - Generic Drug Details

« Back to Dashboard

What are the generic sources for anidulafungin and what is the scope of anidulafungin patent protection?

Anidulafungin is the generic ingredient in one branded drug marketed by Vicuron and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Anidulafungin has sixty-seven patent family members in twenty-nine countries.

There are two drug master file entries for anidulafungin. One supplier is listed for this compound.

Summary for anidulafungin
International Patents:67
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 2
Suppliers / Packagers: 1
Bulk Api Vendors: 33
Clinical Trials: 34
Patent Applications: 2,063
DailyMed Link:anidulafungin at DailyMed
Pharmacology for anidulafungin
Synonyms for anidulafungin
166663-25-8
663A258
9HLM53094I
AC1L4YAI
AKOS030526640
AN-5571
Anidulafungin (LY303366)
Anidulafungin [USAN:INN:BAN]
Anidulafungin [USAN:INN]
Anidulafungina
Anidulafungine
Anidulafunginum
AT-36943
BDBM50417554
C58H73N7O17
CHEBI:55346
CHEMBL264241
DB00362
Ecalta
Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N(sup 2)-((4'-(pentyloxy)(1,1':4',1'-terphenyl)-4-yl)carbonyl)-L-ornithine)-
Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-L-ornithine)
Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4"-(pentyloxy)(1,1':4',1"-terphenyl)-4-yl)carbonyl)-L-ornithine)
Eraxis
J-010304
LS-63738
LY-303366
LY303366
MolPort-006-167-527
N-((2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,12,15-tetrahydroxy-6,20-bis((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxo
N-[[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-tetrahydroxy-bis[(1R)-1-hydroxyethyl]-methyl-hexaoxo-[?]yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
NCGC00386349-01
s4286
SCHEMBL38292
SW222238-1
tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)-4''-(pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxamide
UNII-9HLM53094I
V-Echinocandin
VER-002
Z-3192

US Patents and Regulatory Information for anidulafungin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for anidulafungin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-002 Nov 14, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Vicuron ERAXIS anidulafungin POWDER;INTRAVENOUS 021632-001 Feb 17, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for anidulafungin

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0561639 C300334 Netherlands ➤ Try a Free Trial PRODUCT NAME: ANIDULAFUNGIN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/416/001 20070920
0561639 91406 Luxembourg ➤ Try a Free Trial 91406, EXPIRES: 20180318
0561639 C00561639/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: ANIDULAFUNGIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 58325 03.09.2009
0561639 SPC/GB08/016 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ANIDULAFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/416/001 20070920
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Queensland Health
AstraZeneca
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.